Zoetis Inc., the leading global animal health company, is set to launch its new Vetscan OptiCell™ hematology analyzer, a cutting-edge diagnostic tool that combines cartridge-based technology with AI-powered capabilities for advanced Complete Blood Count (CBC) analysis. Expected to debut in the U.S. later this year, the Vetscan OptiCell offers significant improvements in time, cost, and space efficiency, allowing veterinary teams to enhance patient care and streamline clinic workflows.
Vetscan OptiCell exemplifies Zoetis’ ongoing commitment to innovation in veterinary medicine. This latest addition to Zoetis’ diagnostics portfolio leverages AI-driven cell-focusing and classification technology, delivering lab-quality CBC analysis at the point of care.
Abhay Nayak, Zoetis’ President of Global Diagnostics, emphasized, “This innovation strengthens our hematology offerings, especially when paired with Vetscan Imagyst® AI Blood Smear. Together, they enrich Zoetis’ Virtual Laboratory platform, creating a comprehensive and connected diagnostic solution.”
Dr. Richard Goldstein, Global Chief Medical Officer at Zoetis, added, “Vetscan OptiCell offers accurate results, improved efficiency, and a compact design. For the first time, AI image recognition is used to analyze blood cells, moving beyond traditional methods that rely on size or physical characteristics. This marks a major advance in our hematology capabilities and demonstrates Zoetis’ dedication to animal health and veterinary care.”
The Vetscan OptiCell joins the Vetscan® HM5 as Zoetis’ second hematology analyzer, enhancing in-clinic blood cell analysis. Alongside the AI-powered Vetscan Imagyst analyzer, this suite of diagnostic tools is setting the future of veterinary diagnostics.
The Vetscan OptiCell will be publicly unveiled at the London Vet Show, booth N50, ExCel London, on November 14-15, 2024. U.S. pre-orders will open in late 2024, with a presentation scheduled at VMX in Orlando, January 2025.
Supported by Zoetis’ Virtual Laboratory network of board-certified specialists, this portfolio provides veterinarians with expert pathology insights, advancing patient care to new heights.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries.
